Ocular Therapeutix grants new SVP Beth Rada options for 85,000 shares, 28,000 RSUs under inducement plan
OCUL•Vesting terms
The stock option vests over four years, with 25% vesting after one year and then monthly thereafter; the term is 10 years.
The RSUs vest over three years in equal annual installments, contingent on continued service.
Inducement equity awards for new SVP
Ocular Therapeutix granted inducement equity awards to Beth Rada, its new SVP, Government Affairs and Public Policy.
The package includes a non-statutory stock option for 85,000 shares, priced at $9.24, effective Aug. 10, 2026.
The grant also includes restricted stock units covering 28,000 shares.
Related News
Qiagen supervisory board member Eva Pisa reports “another” transaction in NL0015002SN0 shares; volume not quantifiable
QGEN•
US bonds climb despite 30-year auction drawing highest yield since 2001
TLT•
